By targeting the RANK/RANKL pathway, denosumab offers a molecular approach to treatment that could potentially reduce tumor size, alleviate symptoms, and stabilize lesions without the immediate risks associated with invasive procedures. Here, TNFRSF11A is linked to neoplasm.